Depletion of Regulatory T Lymphocytes Reverses the Imbalance between Pro- and Anti-Tumor Immunities via Enhancing Antigen-Specific T Cell Immune Responses

Yu-Li Chen1,2,3, Ming-Cheng Chang4,6, Chi-An Chen3, Han-Wei Lin4, Wen-Fang Cheng5,4,5*, Chung-Liang Chien1*

1 Graduate Institute of Anatomy and Cell Biology, College of Medicine, National Taiwan University, Taipei, Taiwan, 2 Gynecologic Cancer Center, Department of Obstetrics and Gynecology, Cathay General Hospital, Taipei, Taiwan, 3 Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei, Taiwan, 4 Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan, 5 Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan, 6 Department of Anesthesiology, College of Medicine, National Taiwan University, Taipei, Taiwan

Abstract

Background: The regulatory T cells (Tregs) can actively suppress the immune responses. However, literature about detailed changes of host effective and suppressive immunities before and after depletion of Tregs in ovarian carcinomas is rare.

Materials and Methods: Ovarian cancer patients and the ascitogenic animal model were employed. Immunologic profiles with flow cytometric analyses, immunohistochemical staining, RT-PCR, ELISA, and ELISPOT assays were performed. In vivo depletion of Treg cells with the mAb PC61 was also performed in the animal model.

Results: The cytokines, including IL-4 (p=0.017) and TNF-α (p=0.046), significantly decreased while others such as TGF-β (p=0.013), IL-6 (p=0.016), and IL-10 (p=0.018) were elevated in ascites of ovarian cancer patients, when the disease progressed to advanced stages. The ratio of CD8+ T cell/Treg cell in ascites was also lower in advanced diseases than in early diseases (advanced 7.37±0.64 vs. early 14.25±3.11, p=0.037). The kinetic low-dose CD25 Ab depletion group had significantly lower intra-peritoneal tumor weight (0.20±0.03 g) than the sequential high-dose (0.69±0.06 g) and sequential low-dose (0.67±0.07 g) CD25 Ab deletion groups (p=0.001) after 49 days of tumor challenge in the animal. The kinetic low-dose CD25 Ab depletion group generated the highest number of IFN-γ-secreting, mesothelin-specific T lymphocytes compared to the other groups (p<0.001).

Conclusions: The imbalance between effective and suppressive immunities becomes more severe as a tumor progresses. The depletion of Treg cells can correct the imbalance of immunologic profiles and generate potent anti-tumor effects. Targeting Treg cells can be a new strategy for the immunotherapy of ovarian carcinoma.

Citation: Chen Y-L, Chang M-C, Chen C-A, Lin H-W, Cheng W-F, et al. (2012) Depletion of Regulatory T Lymphocytes Reverses the Imbalance between Pro- and Anti-Tumor Immunities via Enhancing Antigen-Specific T Cell Immune Responses. PLoS ONE 7(10): e47190. doi:10.1371/journal.pone.0047190

Editor: Song Guo Zheng, University of Southern California, United States of America

Received March 20, 2012; Accepted September 12, 2012; Published October 17, 2012

Copyright: © 2012 Chen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The funding for this study was granted by the National Science Committee of Taiwan (NSC 98-2628-B-002-083-MY3 and 100-2314-B-002-O24). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: chien@ntu.edu.tw (C-LC); wenfangcheng@yahoo.com (W-FC)

Introduction

Malignancy is considered a multi-factorial disease and the influence of immunologic mechanisms on cancer progression and prognosis has become an important issue recently. The CD25+CD4+ regulatory T cells (Tregs) actively suppress physiologic and pathologic immune responses, contributing to unresponsiveness to self constituents and non-self antigens. The development and function of Treg cells depend on the expression of the transcription factor fork-head box P3 (FoxP3) [1]. Treg cells are also influenced by cytokines, including IL-2, IL-10 and TGF-β [2], and can suppress immunity through cell-to-cell contact-dependent suppression, cytokine control, and killing of effector cells [3-6]. However, the mechanisms of suppression are not well known.

It is necessary to control the magnitude of Treg-mediated suppression for the benefit of the host because too much suppression will result in more immune suppression and render the host susceptible to infection and cancer [2]. Elevated proportions of Tregs among tumor-infiltrating lymphocytes have been described in many types of cancer, including ovarian carcinoma [7]. In addition, results of several studies have shown that increased Treg infiltration in ovarian cancer is associated with poor survival [8-10].

Conventional modalities for malignancies are surgery, chemotherapy, or radiation therapy. Currently, the standard treatment of ovarian carcinoma is surgical intervention followed by platinum-containing chemotherapy [11,12]. Because of the lack of symptoms and adequate screening methods in the early stage, about 75% of cancer patients are diagnosed as advanced diseases.
[13] and their five-year overall survival rate is only 20–30% [14]. To achieve better ovarian cancer management, many modalities are still being explored. In the viewpoint of immunology, immune manipulation may be an attractive alternative approach because it has the specificity to discriminate between neoplastic and non-neoplastic cells [15]. Although the precise mechanisms of host immune responses to tumor cells are still unclear, malignant tumors have been immunogenic in some cancer sites, including ovarian carcinoma [8,16,17]. Therefore, clinical trials of using immunologic modalities for ovarian cancer patients have been ongoing over the last two decades [18], but the most effective immune manipulation for ovarian carcinoma is still eagerly awaited.

Literature about detailed changes of host effective and suppressive immunities, including immunocytes and cytokine profiles during tumor progression, is rare. Thus, this study used the ascitogenic animal model with WF-3 tumor cell line [19], which can generate tumor sharing similar to the morphologic features of ovarian tumors, to verify the immunologic findings of ascites of ovarian cancer patients. A series of experiments were also designed to explore the dynamically systemic and local immune responses of hosts during tumor progression using this model, while in vivo Treg cells depletion experiments were performed to demonstrate whether the depletion of Tregs could reverse the imbalance between pro- and anti-tumor immunities during tumor progression and if the antigen-specific immunity could be generated. Lastly, through the survival analysis of mice treated with Abs to Tregs, the proposed modality of immune manipulation was investigated in the study.

Materials and Methods

Patients and specimens

Twenty patients (10 early stage diseases and 10 advanced diseases) with ovarian carcinoma undergoing staging or debulking surgery were recruited. Stages I and II diseases were defined as early stages while stages III and IV were defined as advanced stages. The Institutional Review Board reviewed and approved the study protocol. The collection of cancerous tissue, ascites, and peripheral PBMCs were acquired after the patients signed informed consent. These ascites specimens were separated into supernatant and cellular components as described earlier. The ascites were collected directly from mice 49 days after tumor injection. The fluid was collected on day 14 after tumor injection while ascites was collected from mice 49 days after tumor injection. The ascites were separated into supernatant and cellular components as described earlier. The supernatant was stored at −20°C whereas cells defined as tumor-associated cells were stored at −135°C until analysis.

Collection of ascites and tumor-associated cells (TACs)

The WF-3 tumor cells (5 × 10⁴/mouse) were injected intraperitoneally (6 mice per group) and the mice were sacrificed on days 14 and 49 post-injection. One ml phosphate-buffered saline (PBS) was injected into the peritoneal cavity and intra-peritoneal fluid was collected on day 14 after tumor injection while ascites was collected directly from mice 49 days after tumor injection. The ascites were separated into supernatant and cellular components as described earlier. The supernatant was stored at −20°C whereas cells defined as tumor-associated cells were stored at −135°C until analysis.

Surface marker staining and flow cytometry of splenocytes and TACs

For the animal part, the mice were first injected with WF-3 and sacrificed after tumor challenge as described earlier. The splenocytes were treated and obtained as described previously [21]. The splenocytes were then used directly or stored at −135°C until further experiments.

The mice splenocytes and TACs were stained with fluorescein isothiocyanate (FITC)-conjugated anti-mouse CD3 (Biolegend, San Diego, CA), phycoerythrin (PE)-conjugated anti-mouse CD4 (Biolegend), PE-conjugated anti-mouse CD8 (Biolegend), PE/Cy5-conjugated anti-mouse CD4 (eBioscience, San Diego, CA), PE-conjugated anti-mouse CD25 (eBioscience), PE-conjugated anti-mouse CD19 (eBioscience), PE-conjugated anti-mouse NK1.1 (Biolegend), or PE-conjugated anti-mouse CD23 (eBioscience) for different experiments [22]. Flow cytometry assays and analyses were performed using a Becton Dickinson FACScan (Becton Dickinson, Franklin Lakes, NJ) withCELLQuest software.

For the human part, the human TACs were stained with FITC-conjugated anti-human CD3 (Biolegend), FITC-conjugated anti-human Lin (Biolegend), PE-Cy5-conjugated anti-human CD4 (Biolegend), PE-Cy5-conjugated anti-human CD33 (Biolegend), PE-conjugated anti-human CD11b (Biolegend), PE-conjugated anti-human CD8 (BD Biosciences, San Diego, CA), or PE-conjugated anti-human CD25 (Biolegend) in different experiments, and analyzed by flow cytometry as described earlier.

Immuno-histochemistry for CD4+FoxP3+ Treg cells

Immuno-histochemistry studies of Treg cells in murine spleens were performed with some modifications [23]. Briefly, eight-micrometer cryostat sections were obtained from unfixed tissue embedded in optimal cutting temperature (OCT) compound. After fixation with cold methanol (−20°C) for 20 min, the sections were incubated with 5% fetal bovine serum (FBS) for 10 min. Subsequently, the sections were incubated at 4°C overnight with the primary antibody, including rat anti-mouse CD4 antibody (Abcam, Cambridge, MA) and rabbit anti-mouse FoxP3 antibody (Abcam), and then washed three times in PBS for 15 min. After incubation with the primary antibody, the sections were then incubated at room temperature for 1–2 hours with appropriate secondary antibodies like anti-rat secondary antibody-FITC (Abcam) and anti-rabbit secondary antibody-H&L-F(ab)² fragment (Abcam) in PBS containing 0.5% FBS, followed by counter-staining by Hoechst33342 (Sigma-Aldrich, St. Louis, MO). After several washings with PBS, the sections were cover-slipped using anti-fade mounting medium (Invitrogen, Carlsbad, CA) and analyzed by confocal microscopy (Leica TCS SP2, Heidelberg, Germany).

Tumor cell line

The generation of WF-3 tumor cells was as previously described and maintained in RPMI-1640, supplemented with 10% (volume/volume) fetal bovine serum, 50 U/mL penicillin/streptomycin, 2 mM L-glutamine, 1 mM sodium pyruvate, 2 mM non-essential amino acids, and 0.4 mg/mL G418 at 37°C with 5% carbon dioxide [19].

Mice

Six-to-eight week-old female C57BL/6J mice were bred in and purchased from the animal facility of the National Taiwan University Hospital (Taipei, Taiwan). All animal procedures were conducted according to approved protocols and in accordance with recommendations for the proper use and care of laboratory animals.
Characterization of Tregs by flow cytometry

To identify the Treg cells in murine splenocytes and TACs, splenocytes and TACs were first stained with PE/Cy5-conjugated anti-mouse CD4 (eBioscience) and PE-conjugated anti-mouse CD25 (eBioscience) for cell surface markers. Fluorescein isothiocyanate-conjugated anti-mouse Foxp3 (eBioscience) for intracellular staining were performed as described previously [24]. Staining was characterized by flow cytometric analysis as described earlier.

For the human experiments, the TACs of the ascites were stained with PE/Cy5-conjugated anti-human CD4 (Biologend) and PE-conjugated anti-human CD25 (Biologend) for cell surface markers, and Alexa Fluor® 488 anti-human FoxP3 (Biologend) for intracellular staining to identify human Treg cells in ascites. Staining was analyzed by flow cytometry as described earlier.

Extraction of RNA in murine splenocytes and various cytokine expressions by reverse-transcription polymerase chain reaction (RT-PCR)

Total RNA of murine splenocytes was first isolated by TRIzol reagent following the manufacturer’s instructions (Invitrogen). To detect the RNA expression of various cytokines in the splenocytes, RT-PCR with primers specific for interleukin (IL)-4, 6, 10, and 12, tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ) and GAPDH were done. The sequences of PCR primers were listed as follows: mouse IL-4 (forward primer: 5'-TCAACCCC-CAGCTATGGTG-3'; reverse primer: 5'-ATCGAAGGCC- GAAGGT-3'), mouse IL-6 (forward primer: 5'-GTTCCTCTGGAAATGCTGAAGA-3'; reverse primer: 5'-GGAAATTTGGTTAGGAAGAA-3'), mouse IL-10 (forward primer: 5'-TGCATATGCTGCTGCTCTTTCA-3'; reverse primer: 5'-TTTTTCACAGGGAGAAATGACC-3'), mouse IL-12 (forward primer: 5'-CAGCGCTGAAGAAGATGACA-3'; reverse primer: 5'-AGTCCTCTTTGTGTCACCTG-3'), mouse TNF-α (forward primer: 5'-ACCGGCAATGCATCTCAAGAC-3'; reverse primer: 5'-CGGACTCGGCAAGGTCAAG-3'), and mouse IFN-γ (forward primer: 5'-GGGATTCCGCTGCTGCTCTCA-3'; reverse primer: 5'-GGTCGCTATGGTGCTGCTTCA-3'). The GAPDH primer was 5'-ACCCAGAAGACTGTG-ATG-3', and the reverse primer was 5'-TGGGTGAGC- CAAAATTCCGT-3'. The amplification products were separated by 1% agarose gel electrophoresis and visualized after staining with ethidium bromide.

Enzyme-linked immunosorbent assays (ELISA) of cytokines in ascites of WF-3 tumor-bearing mice and ovarian cancer patients

Direct ELISAs of human IL-4, 5, 6, 9, 10, 12, 13, 17, TNF-α, IFN-γ, and transforming growth factor-beta (TGF-β) (e-Bioscience) and murine IL-4, 6, 10, 12, TNF-α, IFN-γ, and TGF-β (e-Bioscience) in ascites were performed based on the manufacturer’s instructions [25].

IFN-γ ELISPOT assays

The ELISPOT assays of mesothelin-specific CD8+ T cells in murine splenocytes were performed with some modifications [26]. The 96-well filtration plates (Millipore, Bedford, MA) were coated with 5 μg/ml anti-mouse INF-γ antibody (BD Biosciences) in 100 μl PBS. After being incubated overnight at 4°C, the wells were washed and blocked with culture medium containing 10% FBS. The mice of various groups were treated and the splenocytes were collected as described earlier.

Different groups of splenocytes were serially cultured with 10 μg/ml mesothelin peptide (aa 406-414) for 48 h at 37°C, 5% CO₂. Following culture, the plate was washed and then incubated with 2 μg/ml biotinylated anti-mouse INF-antibody (BD Biosciences) in 100 μl PBS at 4°C overnight. After subsequent washing, 1.2 μg/ml avidin-alkaline phosphatease (Sigma-Aldrich) in 100 μl PBS was added and the plates were incubated for two hours at room temperature. Afterwards, spots were developed by adding 100 μl 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium solution (Boehringer Mannheim, Indianapolis, IN) and incubation at room temperature for 20 min. The reactions were stopped by discarding the substrate and washing the plates under tap water. The plates were then air-dried and the colored spots were counted using a dissecting microscope.

In vivo antibody depletion experiments

The mAb PC61 (Bio X cell, West Lebanon, NH) was used for in vivo CD25 depletion [27]. Flow cytometric analysis revealed that 95% of the appropriate lymphocyte subsets were depleted, while other lymphocyte subsets remained within normal levels. Briefly, C57BL/6J mice (5 mice per group) were challenged with WF-3 tumor cells intra-peritoneally on day 0. Mice were sacrificed on days 14 or 49 for the immunologic profiling assays and the remaining mice (5 in each group) were kept until they died to obtain overall survival analysis. The total weight of tumors of each mouse was also measured when sacrificed. Depletion was terminated on the day of euthanasia. The splenocytes and ascites were harvested for immunocytes and cytokine analyses as described earlier.

The mAb ID11.17.8 and mAb JES5-2A5 (Bio X cell) were used for in vivo neutralizing the effects of TGF-β and IL-10, respectively [28,29]. In this experiment, the mice (5 mice per group) were challenged with WF-3 tumor cells intra-peritoneally on day 0. It was terminated on day 100. The overall survivals of mice would be analyzed.

Statistical analysis

All of the data were expressed as mean±S.E. (standard error), which represented at least two different experiments. Data for the kinetic changes of immune effectors, regulatory T lymphocytes, cytokine expression, and total tumor weights were evaluated by one-way analysis of variance (ANOVA). The event time distributions for different mice in the survival experiments were compared using Kaplan-Meier method and log rank analysis. A p<0.05 was considered statistically significant.

Results

Immune profiles of immunocytes and cytokines in ascites changed between early- and advanced-stage ovarian cancer patients

The ascites of ovarian cancer patients was analyzed to evaluate the immune components of tumor micro-environment. Representative figures of flow cytometric analysis for various immunocytes, such as CD4+ helper, CD8+ cytotoxic, and regulatory T lymphocytes in ascites were shown in Figure 1A. The percentages of CD4+ helper T cells significantly increased in advanced-staged patients compared to those in patients with early stages (advanced 18.3±3.7% vs. early 3.4±2.6%, p = 0.01, one-way ANOVA) (Fig. 1B1). Similar phenomena were observed in the percentages of CD8+ cytotoxic T lymphocytes (advanced 18.3±2.7% vs. early 4.1±1.7%, p = 0.01, one-way ANOVA) (Fig. 1B2) and Treg cells (advanced 2.5±0.7% vs. early 0.3±0.1%, p = 0.02, one-way ANOVA) (Fig. 1B3). Moreover, the ratios of CD8+ T cell/Treg...
were significantly lower in patients with advanced stages than in patients with early stages (advanced 7.37 ± 0.64 vs. early 14.23 ± 3.11, p = 0.037, one-way ANOVA). However, the percentages of myeloid suppressor cells (MDSCs) in TACs between early- and advanced-stage ovarian cancer patients were not significantly different (p = 0.46, one-way ANOVA, Fig. S1A).

The IL-4 concentrations (10.1 ± 0.5 pg/ml in early stages vs. 7.8 ± 0.8 pg/ml in advanced stages, p = 0.017, one-way ANOVA) (Fig. 1C1) and TNF-α in ascites (8.0 ± 2.3 pg/ml in early stages vs. 2.4 ± 0.7 pg/ml in advanced stages, p = 0.046, one-way ANOVA) (Fig. 1C2) were significantly higher in patients with early-stage than in patients with advanced stages. In contrast, the other cytokines, including TGF-β (122.9 ± 60.4 pg/ml in early stages vs. 300.9 ± 58.5 pg/ml in advanced stages, p = 0.013, one-way ANOVA (Fig. 1C3), IL-6 (83.7 ± 32.0 pg/ml in early stages vs. 287.3 ± 65.3 pg/ml in advanced stages, p = 0.016, one-way ANOVA) (Fig. 1C4), IL-10 (4.3 ± 1.8 pg/ml in early stages vs. 29.9 ± 9.3 pg/ml in advanced stages, p = 0.019, one-way ANOVA) (Fig. 1C5), and INF-γ (1.1 ± 0.1 pg/ml in early stages vs. 2.5 ± 0.4 pg/ml in advanced stages, p = 0.008, one-way ANOVA) (Fig. 1C6) in ascites were higher in patients with advanced stages than in patients with early stages. There were no differences in IL-5 (p = 0.26, one-way ANOVA), IL-9 (p = 0.23, one-way ANOVA), IL-12 (p = 0.54, one-way ANOVA), IL-13 (p = 0.43, one-way ANOVA), and IL-17 (p = 0.06, one-way ANOVA) expression levels between these two groups (Fig. S1B).

In this evaluation of ovarian cancer-related ascites, the expressions of host immune components were not constant between early- and advanced-stage ovarian cancer patients. The percentages of anti-tumor effectors were decreased but the percentage of immune suppressor, Treg, was decreased as the disease progressed in this analysis. The expression levels of various cytokines were also different between early- and advanced-stage diseases.

Percentages of systemic immune effector cells in splenocytes decreased with tumor progression

To further elucidate the dynamic changes of immunity profiles in human ovarian cancer, an ascitogenic animal model was used. The protocol of evaluating immunologic profiles of tumor-bearing mice in early or advanced diseases was shown in Figure 2A. The PBS-challenged mice were used as control (naïve group). Representative figures of tumor-bearing mice in the early and advanced disease stages were shown in Figure 2B. Only small tumors with little ascites were found in mice with early disease. However, disseminated tumor implants with bloody ascites were identified in mice with advanced disease.

Representative figures of flow cytometric analysis of immune effectors, such as CD4+ helper and CD8+ cytotoxic T cells, NK cells, and B lymphocytes in splenocytes, were shown in Figure 2C. The percentages of CD4+ helper T lymphocytes significantly decreased in mice with advanced disease (2.60 ± 0.14%) compared to the naive (19.01 ± 0.80%) or early disease (20.89 ± 0.16%) groups (p < 0.001, one-way ANOVA (Fig. 2D1). However, the percentages of CD8+ cytotoxic T lymphocytes decreased in the early disease (9.13 ± 0.50%), but especially in the advanced disease (1.94 ± 0.07%) compared to the naïve group (14.04 ± 0.99%) (p < 0.001, one-way ANOVA (Fig. 2D2). The percentages of NK cells had similar phenomena as those of CD8+ cytotoxic T lymphocytes (naïve group 4.03 ± 0.79%, early disease 1.87 ± 0.07%, advanced disease 0.34 ± 0.03%, p < 0.001, one-way ANOVA) (Fig. 2D3). The B lymphocyte percentages in various groups were also similar to those of the CD4+ helper T lymphocytes (naïve group 41.40 ± 3.69%, early disease 40.73 ± 2.56%, advanced disease 11.06 ± 1.05%, p < 0.001, one-way ANOVA) (Fig. 2D4).

Between naïve group and early disease group, CD4+ helper T lymphocytes and B lymphocytes did not significantly decrease, but CD8+ cytotoxic T cells and NK cells did. However, all the systemic immune effector cells significantly decreased as compared to the naïve group when the tumor progressed to advanced stage in our results.

Figure 1. Different expressions of immune components in ascites of early- and advanced-stage ovarian cancer patients. (A) Representative figures of flow cytometric analyses of CD4+ helper T cells, CD8+ cytotoxic T lymphocytes, and CD4+CD25+ regulatory T lymphocytes (Treg cells) in TAL. A1, CD4+ helper T cells; A2, CD8+ cytotoxic T lymphocytes; A3, CD4+CD25+ Treg cells. (B) Percentages of CD4+ helper T lymphocytes, CD8+ cytotoxic T lymphocytes, and CD4+CD25+ regulatory T lymphocytes (Treg cells) in TAL. B1, CD4+ helper T cells; B2, CD8+ cytotoxic T lymphocytes; B3, CD4+CD25+ Treg cells. Note: The percentages of CD4+ T cells were significantly higher in patients with advanced stage ovarian cancer. (C) Concentrations of various cytokines in ascites of ovarian cancer patients. C1, IL-4; C2, TNF-α; C3, TGF-β; C4, IL-6; C5, IL-10; C6, IFN-γ. Note: The IL-4 and TNF-α concentrations decreased while the TGF-β, IL-6, IL-10, and IFN-γ concentrations increased from early to advanced stage. doi:10.1371/journal.pone.0047190.g001
Percentages of local immune effector cells in TACs of ascites changed with tumor progression

The change of effector immunocytes in the local tumor environment was then evaluated by flow cytometric analysis. Representative figures of flow cytometric analysis of various immune effector cells were shown in Figure S2. The percentages of CD4⁺ helper T lymphocytes increased as the disease progressed to the advanced stage (naïve 18.6 ± 0.24%, early 21.6 ± 2.65%, advanced 25.4 ± 1.79%, p = 0.002, one-way ANOVA) (Fig. 3A1).

The percentages of CD8⁺ cytotoxic T cells in TACs also increased with disease progression (naïve 5.01 ± 0.26%, early 10.3 ± 2.41%, advanced 14.5 ± 1.81%, p < 0.001, one-way ANOVA) (Fig. 3A2).

In contrast, the percentages of NK cells (naïve 5.12 ± 0.56%, early 3.20 ± 0.32%, advanced 0.93 ± 0.14%, p < 0.001, one-way ANOVA) and B lymphocytes (naïve 53.90 ± 3.03%, early 51.6 ± 1.01%, advanced 25.10 ± 2.69%, p < 0.001, one-way ANOVA) in TACs decreased with disease progression (Figs. 3A3 and 3A4).

The number of T lymphocytes increased in the local tumor environment as the disease progressed, but the numbers of NK cells and B lymphocytes decreased. Moreover, in this intra-peritoneal tumor model, the changes of immune effector cells were different between the systemic (spleen) and the local (ascites) tumor environment as the disease progressed.

The numbers of activated CD8⁺ cytotoxic T lymphocytes in the TACs of ascites did not increase between early and advanced diseases

To further evaluate whether the higher number of CD8⁺ cytotoxic T lymphocytes in the TACs of advanced disease were activated or not, the surface marker expression of CD223, which was the activated marker of T lymphocytes, was detected [30]. Representative figures of

Figure 2. Alterations of systemic immune effector cells in splenocytes of mice challenged with PBS or WF-3 tumor cells. (A) Diagrammatic representation of the collection of specimens in early and advanced diseases. (B) Representative figures of mice after WF-3 challenge at days 14 and 49. Note: Only small tumors (arrow) with little ascites were identified in mice of early disease. However, disseminated tumor implants (arrows) with bloody ascites within the whole peritoneal cavity were noted in mice with advanced disease. (C) Representative figures of flow cytometric analyses of various kinds of lymphocytes in splenocytes. (D) Percentages of various kinds of lymphocytes in splenocytes of naïve mice and in mice of early and advanced diseases. D1, CD4⁺ helper T lymphocytes; D2, CD8⁺ cytotoxic T lymphocytes; D3, NK1.1⁺ natural killer cells; and D4, CD19⁺ B lymphocytes. Note: All of the percentages of systemic immune effector cells significantly decreased as the tumor progressed from early to advanced stage.
activated and non-activated cytotoxic CD8\(^+\) T lymphocytes were shown in Figure 3B1. The percentages of non-activated CD8\(^+\) cytotoxic T lymphocytes in the TACs of the naïve group (94.8 ± 5.2\%), in the early disease group (97.62 ± 1.80\%), and in the advanced disease group (95.80 ± 1.63\%) had no statistical difference (\(p = 0.68\), one-way ANOVA) (Fig. 3B2). Therefore, majority of the CD8\(^+\) cytotoxic T lymphocytes were non-activated as the disease progressed to advanced status. (C) The RT-PCR of various cytokines in splenocytes of mice challenged with PBS or WF-3 tumor cells. Note: The expression levels of IL-4, IL-12, TNF-\(\alpha\), and INF-\(\gamma\) decreased but the expression levels of IL-10 increased gradually as the disease progressed. (D) The concentrations of various cytokines by ELISA in ascites of mice challenged with PBS or WF-3 tumor cells. D1, IL-12; D2, TNF-\(\alpha\); D3, IFN-\(\gamma\); D4, IL-6; D5, IL-10; D6, TGF-\(\beta\). Note: The concentrations of IL-6, IL-10, and TGF-\(\beta\) were elevated but those of IL-12, TNF-\(\alpha\), and IFN-\(\gamma\) decreased as the tumor progressed.

doi:10.1371/journal.pone.0047190.g003

activated and non-activated cytotoxic CD8\(^+\) T lymphocytes were shown in Figure 3B1. The percentages of non-activated CD8\(^+\) cytotoxic T lymphocytes in the TACs of the naïve group (94.8 ± 5.2\%), in the early disease group (97.62 ± 1.80\%), and in the advanced disease group (95.80 ± 1.63\%) had no statistical difference (\(p = 0.68\), one-way ANOVA) (Fig. 3B2). Therefore, majority of the CD8\(^+\) cytotoxic T lymphocytes were not activated in the local tumor micro-environment, although the numbers of CD8\(^+\) T lymphocytes increased as the disease progressed.

Dynamic changes of cytokine profiles in systemic immunity and local tumor environment with various disease severities

The RNA expression levels of various cytokines were evaluated in the splenocytes of mice by RT-PCR as systemic immunity. The RNA expression levels of IL-4, IL-12, TNF-\(\alpha\), and INF-\(\gamma\) decreased as the disease progressed. In contrast, the RNA expression levels of anti-inflammatory cytokines like IL-10 increased (Fig. 3C).

The concentrations of cytokine profiles in ascites as local immunity were further evaluated by ELISA. The concentrations of cytokines like IL-12 (naïve 28.7 ± 5.4, early 3.7 ± 0.2, advanced 1.5 ± 0.2 pg/ml, \(p = 0.001\), one-way ANOVA), TNF-\(\alpha\) (naïve 14.7 ± 1.9, early 7.2 ± 0.6, advanced 3.2 ± 0.5 pg/ml, \(p = 0.001\), one-way ANOVA), and INF-\(\gamma\) (naïve 10.9 ± 0.9, early 2.9 ± 0.6, advanced 0.7 ± 0.3 pg/ml, \(p < 0.001\), one-way ANOVA) decreased gradually as the tumor burden increased (Figs. 3D1–3D3). However, the concentrations of other cytokines, including IL-6 (naïve 70.8 ± 0.5, early 70.7 ± 0.8, advanced 3585.6 ± 53.4 pg/ml, \(p < 0.001\), one-way ANOVA), IL-10 (naïve 0.0 ± 0.0, early 0.0 ± 0.0, advanced 68.8 ± 0.7 pg/ml, \(p < 0.001\), one-way ANOVA), and TGF-\(\beta\) (naïve 17.9 ± 1.5, early 107.5 ± 13.6, advanced 348.9 ± 9.0 pg/ml, \(p < 0.001\), one-way ANOVA) were significantly elevated when the tumor progressed (Figs. 3D4–3D6).

The percentages of Tregs in systemic or local tumor environments increased with disease progression

The changes in immuno-suppressor cells such as regulatory T cells (Tregs) in the systemic and local tumor environments of

Figure 3. Kinetic changes of local immune effector cells in TACs of mice challenged with PBS or WF-3 tumor cells. (A) Percentages of various kinds of lymphocytes in TACs of naïve mice and mice of early and advanced diseases. A1, CD4\(^+\) helper T lymphocytes; A2, CD8\(^+\) cytotoxic T lymphocytes; A3, NK1.1\(^+\) natural killer cells; and A4, CD19\(^+\) B lymphocytes. Note: For helper and cytotoxic T lymphocytes, the percentages on TACs increased from early to advanced disease. However, the percentages of natural killer cells and lymphocytes in TACs significantly decreased with tumor progression. (B) CD223\(^+\)CD8\(^+\) lymphocytes in TACs of mice. B1: Representative figures of flow cytometric analyses of CD223\(^+\) CD8\(^+\) and CD223\(^-\) CD8\(^+\) lymphocytes in TACs. B2: Percentages of CD223\(^+\)CD8\(^+\) lymphocytes in TACs of mice. Note: Majority of CD8\(^+\) cytotoxic T lymphocytes were non-activated as the disease progressed to advanced status. (C) The RT-PCR of various cytokines in splenocytes of mice challenged with PBS or WF-3 tumor cells. Note: The expression levels of IL-4, IL-12, TNF-\(\alpha\), and INF-\(\gamma\) decreased but the expression levels of IL-10 increased gradually as the disease progressed. (D) The concentrations of various cytokines by ELISA in ascites of mice challenged with PBS or WF-3 tumor cells. D1, IL-12; D2, TNF-\(\alpha\); D3, IFN-\(\gamma\); D4, IL-6; D5, IL-10; D6, TGF-\(\beta\). Note: The concentrations of IL-6, IL-10, and TGF-\(\beta\) were elevated but those of IL-12, TNF-\(\alpha\), and IFN-\(\gamma\) decreased as the tumor progressed.
Deletion of Tregs with antigen-specific immunity demonstrated that under low-dose CD25 Ab treatment, Tregs with antigen-specific immunity could enhance effective host anti-tumor immunity. Therefore, we would like to explore the impacts of different treatment protocols with neutralizing TGF-β, neutralizing IL-10 or Treg depletion with monoclonal antibodies, their survival time was longer than that of mice treated with PBS (neutralizing TGF-β group, \(p = 0.03\), log rank test; neutralizing IL-10 group, \(p = 0.002\), log rank test; neutralizing TGF-β and neutralizing IL-10 group, \(p < 0.001\), log rank test) (Fig. 6D2). But, among the mice with monoclonal antibody treatment, those in the kinetic low-dose CD25 Ab group still had the longest survival time with significance when compared to the other mice in the neutralizing TGF-β group, neutralizing IL-10 group and neutralizing TGF-β and neutralizing IL-10 group (\(p < 0.001\), log rank test) (Fig. 6D2).

**Discussion**

Immunogenicity is the ability of antigens to elicit an immune response. Host anti-tumor immunity can be induced because of the existence of tumor-specific and/or tumor-associated antigens. To date, over 1000 human tumor antigens have been established in the human cancer immunome database (http://huadwig-sun5.unil.ch/CancerImmunomeDB/). Ovarian carcinoma has been proven to be immunogenic in previous investigations [16,17,18]. The inflammation of lesion site has been associated, in part, with the existence of tumor-specific and/or tumor-associated antigens.

**Depletion of Tregs with in vivo kinetic low-dose CD25 Ab enhanced the anti-tumor immunologic profiles**

To elucidate the influence of host immunity in WF-3-challenged mice undergoing kinetic low-dose CD25 Ab immunologic profiles were evaluated. Mice treated with kinetic low-dose CD25 Ab had significantly higher concentrations of IL-2 (\(p < 0.001\), one-way ANOVA) (Fig. 6A1), IL-12 (\(p = 0.048\), one-way ANOVA) (Fig. 6A2), TNF-α (\(p < 0.001\), one-way ANOVA) (Fig. 6A3), and INF-γ (\(p = 0.036\), one-way ANOVA) (Fig. 6A4), but lower concentrations of TGF-β (\(p = 0.007\), one-way ANOVA) (Fig. 6A5) in ascites compared to the other groups.

The kinetic low-dose CD25 Ab depletion group also had significantly higher percentages of CD8+ cytotoxic T lymphocytes (\(p < 0.001\), one-way ANOVA) (Fig. 6B1) and CD8+ cytokotoxic T lymphocytes (\(p < 0.001\), one-way ANOVA) (Fig. 6B2) in splenocytes than in PBS and the other two sequential CD25 Ab depletion groups after 49 days of WF-3 tumor challenge. In contrast, the kinetic low-dose CD25 Ab depletion group had lower percentages of T cells (\(p = 0.045\), one-way ANOVA) (Fig. 6B3).

The ratios of CD8+ cytokotoxic T cells/Treg cells of the TACs in the kinetic low-dose CD25 Ab depletion group were also highest among the naive, PBS-treated, and the three CD25 Ab depletion groups (\(p < 0.001\), one-way ANOVA) (Fig. 6B4). However, the percentages of CD4+ helper T cells (\(p < 0.001\), one-way ANOVA) (Fig. 6B1), CD8+ cytokotoxic T cells (\(p < 0.001\), one-way ANOVA) (Fig. 6B2), or Treg cells (\(p = 0.22\), one-way ANOVA) (Fig. 6B3) in the splenocytes were not different between these groups after the 14-day WF-3 tumor challenge.

In addition, this study evaluated if the in vivo CD25 Ab depletion could generate anti-tumor effects via enhancing antigen-specific immunity using mesothelin, a novel ovarian tumor-associated antigen. Representative figures of mesothelin-specific INF-γ ELISPOT assays of splenocytes were shown in Figure 6C1. The kinetic low-dose CD25 Ab depletion group generated the highest numbers of INF-γ-secreting, mesothelin-specific T lymphocytes (33.7 ± 2.0) compared to the other groups after 14 days of WF-3 tumor challenge (PBS group 16.0 ± 2.3, sequential high dose CD25 Ab group 32.0 ± 4.6, sequential low dose CD25 Ab group 22.0 ± 1.2, \(p < 0.001\), one-way ANOVA) (Fig. 6C2).

These above-mentioned results demonstrated that kinetically depleting the immuno-suppressive Treg cells could enhance effective host anti-tumor immunity. Therefore, we would like to explore the impacts of different treatment protocols with neutralizing TGF-β, neutralizing IL-10 or Treg depletion with monoclonal antibodies, their survival time was longer than that of mice treated with PBS (neutralizing TGF-β group, \(p = 0.03\), log rank test; neutralizing IL-10 group, \(p = 0.002\), log rank test; neutralizing TGF-β and neutralizing IL-10 group, \(p < 0.001\), log rank test) (Fig. 6D2). But, among the mice with monoclonal antibody treatment, those in the kinetic low-dose CD25 Ab group still had the longest survival time with significance when compared to the other mice in the neutralizing TGF-β group, neutralizing IL-10 group and neutralizing TGF-β and neutralizing IL-10 group (\(p < 0.001\), log rank test) (Fig. 6D2).
recruitment, phenotype, and function. These can result in the accumulation of naive and/or functionally erroneous T cell sub-populations at such sites [31,32]. In the present analysis of human and murine ascites, the percentages of CD4^+ and CD8^+ T lymphocytes in the TACs of ascites are significantly increased in advanced disease compared to early stage disease (Figs. 1 and 3).

However, the homeostasis between effective and suppressive immunities, including cytokines and immunocytes, has an important impact on tumor progression. When diseases progress to advanced stages, the expressions of pro-inflammatory cytokines such as IL-4 and TNF-α are significantly suppressed [33,34]. Other reports have also shown that increased anti-inflammatory cytokines like IL-10 and TGF-β can help Tregs suppress the function of antigen-presenting cells and arrest the activation of effector T lymphocytes during tumor progression [2,35,36]. In the present analysis of human ascites, pro-inflammatory cytokines are significantly lower and anti-inflammatory cytokines are significantly higher in advanced disease compared to early stage disease (Fig. 1C).

Figure 4. Kinetic changes of Treg cells in the splenocytes and TACs of mice challenged with PBS or WF-3 tumor cells. (A) Representative figures of CD4^+FoxP3^+ Treg cells in the spleen of mice by immuno-histochemistry staining observed under confocal microscopy. A1, A single CD4^+FoxP3^+ regulatory T cell (blue: nucleus, green: CD4, red: FoxP3); A2, PBS group; A3, WF-3 group with early disease; A4, WF-3 group with advanced disease (arrows: CD4^+FoxP3^+ Treg cells). (B) CD4^+CD25^+FoxP3^+ Treg cells in splenocytes. B1: Representative figures of flow cytometric analyses. B2: The bar figures of CD4^+CD25^+FoxP3^+ Treg cells in various groups. B3: The ratios of CD4^+CD25^+FoxP3^+ Treg cells. Note: Referenced with the naive group, Treg cells of the advanced stage group were 1.5-fold higher in splenocytes. (C) CD4^+CD25^+FoxP3^+ Treg cells in TACs. C1: Representative figures of flow cytometric analyses. C2: The bar figures of CD4^+CD25^+FoxP3^+ Treg cells in various groups. C3: The bar figures of the ratios of CD4^+CD25^+FoxP3^+ Treg cells. Note: Referenced with the naive group, Treg cells were 2.9-fold higher in TACs of the advanced stage group.

doi:10.1371/journal.pone.0047190.g004

T lymphocytes are a major component of cellular immune response and are the essential cells required for anti-tumor immunity [35]. For ovarian carcinoma, tumor specific CD8^+ T cells can induce autologous tumor cell lysis in vitro [44]. However, the CD4^+CD25^+FoxP3^+ Tregs suppress tumor-specific T-cell immunity and increased Tregs in the tumor micro-environment can be related to the disease severity and poor outcome of ovarian

not identical, which can be explained by the fact that aside from immuno-surveillance, high levels of INF-γ in advanced diseases can generate tumor variants with reduced immunogenicity, which is related to the process of “cancer immuno-editing” [37–40].

IL-17 is involved in mediating inflammatory responses [41,42]. Less amount of IL-17 can be detected in more advanced ovarian cancer-associated ascites (p = 0.03) [43]. However, the expression level of IL-17 in early-stage ovarian cancer is only marginally significantly (p = 0.06) higher than that in advanced disease (Fig. S1B5) in our analysis. This is because that the number of ovarian cancer patients in this study is small (only 20 cases). As more patients could be recruited, the expression level of IL-17 between early- and advanced-disease might be significant. The correlation between the level of IL-17 and clinical outcomes of ovarian cancer patients could also be elucidated.
Carcinoma [7,8]. Sato et al. have also demonstrated that the survivals of ovarian cancer patients with high versus low CD8$^+$ Treg ratios are 58 versus 23 months ($p = 0.0002$) [45]. In the present animal model, the increased percentages of Tregs are noted in systemic (splenocytes) and local (TACs) immunities during tumor progression (Fig. 4), but the alterations of CD8$^+$ T cells are different (Figs. 2D2 and 3B2). When the ratios of murine CD8$^+$ T cell/Treg in splenocytes and TACs are further analyzed, the ratios are lower in advanced disease than in early disease. Thus, alterations of ratios of CD8$^+$ T cell/Treg can better illustrate disease severity rather than the changes of percentages of immunocytes. Moreover, even though the CD8$^+$ T lymphocytes of TACs increase during tumor progression (Fig. 2D2), most of the CD8$^+$ cytotoxic T lymphocytes are not activated in the present study (Figs. 3C and 3D).

The reduction of Tregs or the attenuation of their function can increase anti-tumor immunity and effects [8,27,46,47]. In the present animal model, there are decreased total tumor volumes and weights, and longer survival in the mice with Treg cells depleted by CD25 monoclonal antibody than in those treated with PBS only (Fig. 5). Kinetic low-dose antibody depletion of Treg cell can generate anti-tumor immunity by enhancing the pro-inflammatory cytokines and the anti-tumor effector lymphocytes, including antigen-specific IFN-$\gamma$-secreting CD8$^+$ T cells (Fig. 6A–6C). In addition, those mice treated with kinetic low-dose CD25 Ab would have the longest survival time when compared to the other mice treated with neutralizing TGF-$\beta$ Ab, neutralizing IL-10 Ab and neutralizing TGF-$\beta$ and neutralizing IL-10 Abs (Fig. 6D). The reason might be that Treg cells can suppress host immunity through cell-to-cell contact-dependent suppression, cytokine con-
Regulatory T Cells with Antigen-Specific Immunity

Figure 6. The concentrations of cytokine profiles in ascites and kinetic changes of various lymphocytes in splenocytes of WF-3-challenged mice treated with PBS or CD25 monoclonal antibody. (A) Concentrations of various cytokines in ascites. A1, IL-6; A2, IL-12; A3, TNF-α; A4, IFN-γ; A5, TGF-β. Note: Compared to mice treated with PBS only, the concentrations of cytokines like IL-6, IL-12, TNF-α, and IFN-γ were significantly elevated in mice treated with kinetic low-dose CD25 antibody than those in the other groups. The concentrations of TGF-β significantly decreased in the kinetic low-dose CD25 Ab group compared to the other groups. (B) Percentages of various lymphocytes. B1, CD3+CD4+ helper T lymphocytes. Note: The percentages of CD4+ T lymphocytes in the splenocytes were not different between the PBS and CD25 Ab depletion groups on day 14 after WF-3 tumor challenge. However, the kinetic low-dose CD25 Ab depletion group had higher percentages of CD4+ helper T cells than the PBS and the other two sequential CD25 Ab depletion groups after 49 days of tumor challenge. B2, CD3+CD8+ cytotoxic T lymphocytes. Note: The percentages of CD8+ T cells were not different between the PBS and CD25 Ab depletion groups on 14 days after tumor challenge. The kinetic low-dose CD25 Ab depletion group had higher percentages of CD8+ cytotoxic T cells than the other groups on day 49 after tumor challenge. B3, CD4+CD25+Foxp3+ Treg cells. Note: The percentages of Treg cells in the splenocytes were not different among these groups on day 14 after tumor challenge. However, the kinetic low-dose CD25 Ab depletion group had lower percentages of Treg cells than the other groups on day 49. B4, ratios of cytokotic T lymphocytes/Treg cells. Note: The ratios of CD8+ cytotoxic T cells/Treg cells in the kinetic low-dose CD25 Ab depletion group were highest among the four groups. C) Mesothelin-specific IFN-γ ELISPOT assays of splenocytes in the PBS and CD25 Ab-treated groups. C1, the representative figures of mesothelin-specific IFN-γ ELISPOT assays of splenocytes; C2, bar figures of the numbers of IFN-γ-secreting, mesothelin-specific T lymphocytes in various groups. Note: The kinetic low-dose CD25 Ab depletion group generated the highest numbers of IFN-γ-secreting, mesothelin-specific T lymphocytes compared to the other groups. (D) Survivals of mice treated with PBS, neutralizing TGF-β, neutralizing IL-10 or CD25 monoclonal antibodies. D1, Diagrammatic representation of the different treatment protocols of neutralizing TGF-β, neutralizing IL-10 or CD25 monoclonal antibody; D2, Survival curves of mice treated with PBS, neutralizing TGF-β, neutralizing IL-10, neutralizing TGF-β and neutralizing IL-10 or CD25 monoclonal antibody. Note: The mice treated with kinetic low-dose CD25 Ab had the longest survival time after WF-3 tumor challenge when compared to the other mice treated with PBS, neutralizing TGF-β, neutralizing IL-10 or neutralizing TGF-β and neutralizing IL-10 monoclonal antibodies.

For suppressing the function of Treg cells to enhance anti-tumor immunity, monoclonal antibodies specific to cell surface molecules that are predominantly expressed by Tregs or those specifically able to modulate Treg function have been developed. In addition to CD25 monoclonal antibody, other antibodies for cell surface molecules, including Toll-like receptor (TLR), Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), glucocorticoid- induced TNF receptor (GTR), OX40, and folate receptor 4 (FR4), have been developed [46]. However, an appropriate biomarker is needed to precisely monitor the responsiveness of the treated subjects. In the present survey, there are trends of CD8+ T cells/Treg correlating well with alterations of systemic effector cells after Treg depletion (Fig. 6B). Nonetheless, these ratios still will not reflect the real changes of cytokines (Fig. 6A) and antigen-specific immunity (Fig. 6C) when Tregs are modulated.

In conclusion, the imbalance between effective and suppressive immunities can be identified during disease progression. This phenomenon can be reversed by the depletion of immunosuppressive Treg cells, especially the effective depletion. Tumor
antigen-specific immunity may be enhanced when starting the depletion of Treg cells. The development of new strategies for effective depletion of Treg cells will become an important strategy for cancer immunotherapy.

Supporting Information

Figure S1 Different expressions of immune components in ascites of early- and advanced-stage ovarian cancer patients. (A) Expression of CD11b+CD33−Lin− myeloid suppressor cells in TACs of early- and advanced-stage ovarian cancer patients. (A1) Representative figures of flow cytometric analyses of myeloid suppressor cells in TACs. (A2) Percentages of myeloid suppressor cells in TACs. (B) Concentrations of various cytokines in ascites of ovarian cancer patients. B1, IL-5; B2, IL-9; B3, IL-12; B4, IL-13; B5, IL-17. Note: The concentrations of these cytokines in ascites between early- and advanced-stage ovarian cancers did not alter significantly. (TIF)

Figure S2 Representative figures of flow cytometric analyses of various kinds of local immune effectors in TACs of mice challenged with PBS or WF-3 tumor cells. (TIF)

Acknowledgments

This work was supported in part by the 2nd and 7th core laboratory facility of the Department of Medical Research of National Taiwan University Hospital.

Author Contributions

Conceived and designed the experiments: WFC, CLC. Performed the experiments: YLC, MCC, HWL. Analyzed the data: CAC, WFC, CLC. Contributed reagents/materials/analysis tools: YLC, CAC, WFC. Wrote the paper: YLC, WFC, CLC.

References

1. Sakaguchi S (2004) Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune response. Annu Rev Immunol 22: 531–552.
2. Sakaguchi S, Miyaara M (2007) Natural regulatory T cells: mechanisms of suppression. Trends Mol Med 13: 188–196.
3. Amacker O, Pimenta-Araujo R, Burden-Defrancou X, Barbosa TC, Camuno A, et al. (2001) CD4+ CD25+ T cells regulate the expansion of peripheral CD4+ T cells through the production of IL-10. J Immunol 166: 3008–3018.
4. Nakamura K, Kitani A, Fuss I, Pedersen A, Harada N, et al. (2004) TGF-β1 plays an important role in the mechanism of CD4+ CD25+ regulatory T cell activity in both humans and mice. J Immunol 172: 834–842.
5. Grossman JW, VerbSky JW, Barchet W, Colonna M, Atkinson JP, et al. (2004) Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 21: 589–601.
6. Ghiringhelli F, Ménard C, Terme M, Flament C, Taieb J, et al. (2005) CD4+ CD25+ regulatory T cell inhibit natural killer cell functions in a transforming growth factor-β-dependent manner. J Exp Med 202: 1073–1083.
7. Banchere-Allan C, Anderson DE (2006) Regulatory cells and human cancer. Semin Cancer Biol 16: 98–105.
8. Curiel TJ, Coskols G, Zou L, Alvarez X, Cheng P, et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942–949.
9. Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeinert AG, et al. (2005) The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 11: 4326–4331.
10. Leefjes N, Gooden MJ, de Jong RA (2009) Prognostic significance of tumor-infiltrating lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immuno Ther 58: 449–459.
11. Agarwal R, Kaye SB (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3: 502–516.
12. DiSaia PJ, Bless JD (2003) Treatment of ovarian cancer: new strategies. Gynecol Oncol 90: 824–832.
13. Pfleiderer A (1984) Diagnosis and staging of ovarian cancer. J Cancer Res Clin Oncol 107: 81–88.
14. Gonzalez-Diez P, Lopez-Abente G, Pollan M, Ruiz M (2000) Time trends in ovarian cancer mortality in Europe (1953–1993): effect of age, birth cohort and period of death. Eur J Cancer 36: 816–824.
15. Bree T, Creotini JC, Van den Eynde B, van der Bruggen P, Van Pelt A (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12: 337–367.
16. Zhang L, Conejo-Garcia JR, Kastaras D, Gimmotti PA, Massobrio M, et al. (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 203–213.
17. Tomosova M, Melihar B, Sellakova I, Steiner I (2008) Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol 108: 415–420.
18. Chu CS, Kim SH, June CH, Coskols G (2008) Immunotherapy opportunities in ovarian cancer. Expert Rev Anticancer Ther 8: 243–257.
19. Cheng WF, Hung CF, Chai CY, He L, et al. (2001) Enhancement of simvastatin virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lyosomal compartments. Hum Gene Ther 12: 253–252.
20. Liao CW, Chen CA, Lee CN, Su YN, Chang MC, et al. (2005) Fusion protein vaccine by domains of bacterial exotoxins linked with a tumor antigen generates potent immunologic responses and antitumor effects. Cancer Res 65: 9089–9098.
21. Cheng WF, Hung CF, Chai CY, Hsu KB, He L, et al. (2001) Enhancement of simvastatin virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene. J Immunol 166: 6218–6226.
22. Cheng WF, Lee CN, Su YN, Chang MC, Hsiao WC, et al. (2005) Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations. Immunology 115: 136–149.
23. Imai H, Saiou M, Nonaka K, Unemura N, Ouyang GF, et al. (2007) Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma. Cancer Sci 98: 416–423.
24. Fayrin LM, Read S, Goulvik L, Hurst SD, Coffman RL, et al. (2005) T cells that cannot respond to TGF-beta escape control by CD4+CD25+ regulatory T cells. J Exp Med 201: 737–746.
25. Li Q, Carr A, Ito F, Teitz-Tennenbaum S, Chang AE (2003) Polarization effects of IFN-β on CD8+ dendritic cells in co-culture to generate tumor-reactive T cells for cancer immunotherapy. Cancer Res 63: 2546–2552.
26. Workman CJ, Rice DS, Dugger JK, Kurschner C, Vignali DA (2002) Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3). Eur J Immunol 32: 2255–2263.
27. den Boer AT, van Mierlo GJ, Fransen MF, Melief CJ, Offringa R, et al. (2005) CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T cell responses in tumor-bearing hosts. Cancer Res 65: 6898–6909.
28. Lawrence CW, Bracieja TJ (2004) Activation, differentiation and migration of naïve virus-specific CD8+ T cells during pulmonary influenza virus infection. J Immunol 173: 1209–1218.
29. Golombok PT, Laureby AJ, Levitsky HI, Jaffe LM, Karasuyama H, et al. (1991) Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254: 713–716.
30. Lejune FJ (2002) Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability. J Clin Invest 110: 433–435.
31. Yagi R, Massager LF, Figdor CG, Torensma R (2010) Ovarian cancer creates a suppressive micro-environment to escape immune elimination. Gynecol Oncol 117: 366–372.
32. Kryczek I, Wei S, Zhu G, Myers L, Mottram P, et al. (2007) Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 67: 8900–8905.
33. Shankaran V, Berka H, Bruce AT, White JM, Swanson PE, et al. (2001) IFN-γ mimics and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107–1111.
34. Dunn GP, Bruce AT, Berka H, Old IJ, Schreiber RD (2002) Cancer immunomodulation from immuno-surveillance to tumor escape. Nat Immunol 3: 991–998.
39. Hallermalm K, Seki K, De Geer A, Motyka B, Bleackley RC, et al. (2008) Modulation of the tumor cell phenotype by IFN-gamma results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes. J Immunol 180: 3766–3774.
40. Malmberg KJ, Levinsky V, Norell H, de Matos CT, Carlsten M, et al. (2002) IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J Clin Invest 110: 1515–1523.
41. Wynn TA (2005) TH-17: a giant step from TH1 and TH2. Nat Immunol 6: 1069–1070.
42. Dong C (2006) Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nat Rev Immunol 6: 329–333.
43. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, et al. (2009) Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114: 1141–1149.
44. Ioannides CG, Platsoucas CD, Rashed S, Wharton JT, Edwards CL, et al. (1991) Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res 51: 4257–4265.
45. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, et al. (2005) Intra-epithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102: 18538–18543.
46. Nishikawa H, Sakaguchi S (2010) Regulatory T cells in tumor immunity. Int J Cancer 127: 759–767.
47. Chen CA, Ho CM, Chang MC, Sun WZ, Chen YL, et al. (2010) Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis. Mol Ther 18: 1233–1243.
48. Tsuji NM, Mizumachi K, Kurisaki J (2003) Antigen-specific, CD4+CD25+ regulatory T cell clones induced in Peyer’s patches. Int Immunol 15: 525–534.
49. Freeman CM, Chiu BC, Stolberg VR, Hu J, Zeibecoglou K, et al. (2005) CCR8 is expressed by antigen-elicited, IL-10-producing CD4+CD25+ T cells, which regulate Th2-mediated granuloma formation in mice. J Immuinol 174: 1962–1970.
50. Larmonier N, Marron M, Zeng Y, Cantrell J, Romanoski A, et al. (2007) Tumor-derived CD4+CD25+ regulatory T cell suppression of dendritic cell function involves TGF-β and IL-10. Cancer Immunol Immunother 56: 48–59.